An Adaptive Intervention for Depression Among Latinos Living With HIV: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for An Adaptive Intervention for Depression Among Latinos Living With HIV (NCT03668379), a randomized na study. The primary outcome is Composite Measure of Feasibility for the Adaptive Treatment Strategy (ATS).

2. Clinical Question

The clinical question is therefore primarily about feasibility and acceptability, rather than whether one treatment is more effective than another. The planned strategy was to use behavioral treatments and mHealth in a sequence that could adapt treatment according to a participant’s response. The registry record describes a pilot sequential multiple assignment randomized trial, or SMART, intended to build such a strategy for depression and engagement in HIV care.

The record lists self-reported adherence to antiretroviral therapy, viral load, PHQ-9, and engagement in HIV care among secondary outcomes. It does not report numerical results for these measures. Nor does it provide enough information to assess how depression or engagement changed over time, or to compare the two initial treatment groups on those outcomes.

3. Trial Design

This was a randomized, double-masked, sequential-model study with enrollment of 10 participants. Its stated purpose was to pilot a SMART design and develop an adaptive treatment strategy for depression and engagement in HIV care among Latinos living with HIV. The sponsor was the University of California, San Francisco. The registry lists the study status as completed.

The initial treatment options described were BAT alone and BAT combined with mHealth. The BAT description specifies five one-hour sessions delivered every two weeks. The mHealth component is described as one-way and two-way SMS text messages. The registry also names strategies involving maintenance, adding mHealth, switching to CBT and mHealth, or adding BAT and mHealth. These later options reflect the adaptive-strategy framework, but the reported participant flow did not reach a later re-randomization stage.

In a SMART, participants can be randomized at more than one decision point, with later treatment assignment depending on response to earlier treatment. That structure can support evaluation of treatment sequences rather than only a single initial assignment. In this study, the registry says all participants assigned to first-stage treatment either responded and entered maintenance or did not complete the intervention. It also states that there were no nonresponders and no re-randomized participants who received an augmented or changed first-stage treatment.

The record gives a start date of 2020-02-26 and a primary completion date of 2022-08-28. The randomization procedure, masking details, allocation ratio, and criteria used to define response are not reported in the registry record. The record lists phase as NA. Further details about the intended sequence and implementation are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Stage 1 Intervention (Months 1-2)

Stage 2 Intervention (Months 3-4)

Analysis population for the primary outcome, as defined in the registry: In this study, all participants assigned to their 1st stage treatment either responded and entered the maintenance arm or did not complete the intervention. Thus, we had no non-responders and no re-randomized participants who would have either augmented or changed their 1st stage treatment. Results reflect this result and zero cells in the other arms.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Composite Measure of Feasibility for the Adaptive Treatment Strategy (ATS), measured over 4 months.

The primary endpoint was a composite measure of feasibility for the adaptive treatment strategy, expressed as a count of participants and assessed at four months. Its stated purpose was to judge whether the strategy was appropriate for further testing, relevant, and sustainable. This makes feasibility, rather than comparative clinical efficacy, the focus of the primary endpoint.

The composite included the total number of participants screened, eligible, and enrolled; whether at least 80% of BAT and CBT sessions were completed; and whether 80% of participants were retained across outcome groups. These components represent different practical aspects of carrying out the strategy: reaching and enrolling a target population, delivering treatment as intended, and retaining participants for outcome assessment.

A composite can provide a compact way to describe several implementation goals, but its interpretation depends on how each component is defined and whether the components are all achieved. A single count does not necessarily reveal which aspect of feasibility was difficult or successful. The registry record does not report the numerical composite result, component-level results, or a rule for combining the components into a final score. The record also does not report a comparison of the composite between the initial treatment groups.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The study is described as a pilot sequential multiple assignment randomized trial. General statistical context helps explain why that design differs from a conventional trial with one treatment assignment. In a SMART, treatment can be assigned at an initial stage and, for participants meeting specified conditions, assigned again at a later decision point. The resulting treatment paths can be used to study adaptive strategies: rules that select a later treatment based on earlier response or another clinical status. The registry record does not report the full decision rules or the operational definition of response.

What does randomization contribute?

In general, randomization assigns participants by chance to treatment options. If implemented as planned, it can reduce systematic differences between groups at the point of assignment. It does not guarantee that groups will be balanced on every characteristic, particularly in a small pilot. The registry record labels the study randomized, but the randomization method, allocation ratio, and any stratification factors are not reported in the registry record. The record labels masking as double; which individuals were masked and how masking was maintained are not reported in the registry record.

Why use a sequential design?

General rationale for a sequential design is that treatment needs may change as response becomes known. A design with repeated randomization can evaluate different sequences, including continuation, augmentation, or switching. This study’s descriptions name BAT, CBT, and mHealth-based strategies. However, the participant-flow statement says no nonresponders were re-randomized and no participants received an augmented or changed first-stage treatment. That means the registry record does not provide participant data for comparing the later-stage options as randomized treatment choices. It also does not report a statistical analysis of the adaptive strategies.

What is the primary endpoint measuring?

The primary measure is a count-based feasibility composite assessed at four months. Its stated elements concern the number screened, eligible, and enrolled, completion of at least 80% of BAT and CBT sessions, and 80% retention across outcome groups. These components address recruitment, delivery, and follow-up. In general, a composite outcome combines multiple criteria into a single summary, but the meaning of that summary depends on whether the components are reported separately and on the rule used to combine them. The registry does not report component results, a numerical composite, or the combination rule.

How should uncertainty be understood?

For any estimated effect, a confidence interval communicates statistical uncertainty by showing a range of values compatible with the observed data under the model’s assumptions. A narrow interval indicates greater precision than a wide interval. A p-value, when used, describes how unusual data at least as extreme as those observed would be under a specified null hypothesis and model; it does not measure the probability that a treatment is effective. Neither a confidence interval nor a p-value for the primary endpoint is reported in the registry record. The record lists zero statistical analyses, so the analysis methods for the outcomes are not reported in the registry record.

General statistical methods for count outcomes depend on how counts arise and how variable they are. If counts vary more than a simple model assumes, over-dispersion can make standard errors too small and uncertainty intervals too narrow unless the model accounts for the extra variation. That is a general consideration, not a claim about the analysis of this trial. The registry record does not report a model, an over-dispersion assessment, covariate adjustment, or a missing-data method.

How do planning illustrations differ from trial results?

General sample-size planning illustrations use assumptions about the effect to detect and the statistical method. The illustrations associated with this record use a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the target effect expressed as a fraction of the observed effect. They are planning illustrations, not observed power and not evidence that the trial was adequately powered. The registry record’s own sample-size justification is not reported. No result for the primary composite is available to interpret as an observed treatment effect, and the record does not report a primary-endpoint comparison.

In general, power is a design-stage probability tied to a particular assumed effect, analysis, and significance threshold. It is not a property that can be inferred from whether a study result is statistically significant or from the size of an observed p-value. In this pilot, the stated purpose was to assess feasibility and acceptability and to build an adaptive strategy. The record does not describe a confirmatory statistical plan, an interim analysis, or a sample-size rationale.

Six outcome measures are listed in the registry, while the primary outcome is described as having several categories or time points and is not reduced to one comparison. The study record does not report the analysis population definitions, endpoint-specific estimands, or a strategy for linking the multiple outcomes to a single conclusion. Accordingly, statistical interpretation should remain limited to the design and descriptive information that the record actually reports.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists a composite primary measure and several secondary outcomes, including ART adherence, viral load, PHQ-9, and engagement in HIV care. It also reports six outcome measures in total. When multiple outcomes, time points, or treatment pathways are evaluated, there can be more opportunities to observe an apparently unusual result by chance. General approaches to multiplicity include defining a primary hypothesis in advance, adjusting inference across a family of tests, or treating secondary analyses as exploratory. The registry record does not report a multiplicity plan or a hierarchy for interpreting the outcomes.

The record indicates that the primary outcome has several categories or time points and is not reduced to one comparison. It does not report a statistical analysis for that endpoint. No p-values or confidence intervals for the primary or secondary outcomes are reported in the registry record. As a result, there is no posted inferential result from which to judge how multiplicity was handled.

Missing-data information is also limited. The participant-flow description says participants either responded and entered maintenance or did not complete the intervention, but it does not give a breakdown of missing outcome data or explain how incomplete observations were handled. The registry record does not report imputation, complete-case analysis, sensitivity analysis, or another missing-data method. It also does not define analysis populations, such as an intention-to-treat population. These omissions prevent assessment of whether missingness or exclusions could affect the endpoint summaries.

In general, missing outcomes can reduce precision and may bias an estimate when the reasons for missingness are related to outcomes or treatment. The direction and size of any such effect cannot be determined without participant-level flow and analysis details. No conclusion about missing-data bias is supported by the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event record lists two groups: BAT and BAT with mHealth. In each group, five participants were at risk. The record lists zero participants with a serious adverse event in each group, zero with other adverse events in each group, and zero deaths in each group. No serious adverse-event terms are listed.

These are counts from a study with few participants. General interpretation of a zero count requires caution: it means no events were recorded among the participants at risk in the registry listing, not that the risk of an event is absent. With a small group, uncommon events may not occur during observation even when they remain possible. The record does not report event definitions, collection procedures, observation time by participant, or whether events were assessed for relatedness to treatment.

The adverse-event counts do not establish a safety comparison between treatment options. They are descriptive, and the record does not report a statistical analysis of safety outcomes. The absence of listed events should therefore be read as a feature of the posted counts, not as proof of no safety risk or as a basis for treatment decisions.

12. What the Result Does, and Does Not, Mean

The record documents a pilot study designed to examine whether an adaptive treatment strategy could be implemented for depression and engagement in HIV care among Latinos living with HIV. It describes two initial approaches, BAT alone and BAT with mHealth, and defines a feasibility composite involving recruitment, session completion, and retention. The study enrolled 10 participants and is marked completed in the registry.

The posted results do not include the numerical primary composite, component-level feasibility results, or statistical comparisons between initial treatment groups. They also do not include numerical results for the listed secondary outcomes. Therefore, the record does not establish whether the strategy met its feasibility criteria, whether one initial approach performed differently from the other, or whether any clinical outcome changed.

The adaptive design is an important part of the study’s intended contribution, but the participant-flow description says no nonresponders were re-randomized to augmented or changed treatment. The record therefore does not evaluate those later treatment assignments through randomized comparisons. The result should not be interpreted as a test of every treatment sequence named in the intervention descriptions.

General statistical reasoning also calls for caution with small pilot studies. A small number of participants can make estimates unstable and imprecise, and a lack of a reported difference would not establish equivalence. In this case, treatment-effect estimates and uncertainty intervals are not reported at all, so even their direction and precision cannot be assessed from the registry record.

What the record does support is a description of the study’s aims, design labels, intervention components, feasibility criteria, and reported participant flow. What it does not support is a conclusion about clinical benefit, comparative effectiveness, the success of the feasibility thresholds, or the safety of either approach beyond the posted event counts. Those boundaries are especially important because the primary endpoint was a feasibility composite rather than a direct estimate of treatment effect.

13. Why This Trial Matters Statistically

This trial is statistically notable because it applies a sequential randomized design to a pilot question about adaptive treatment for depression and engagement in HIV care. A SMART can, in general, be useful when treatment is intended to change in response to an individual’s earlier outcome. It can support evaluation of treatment sequences, rather than limiting the research question to a single initial assignment. Such designs also require clear decision rules, adequate numbers at each stage, and reporting that distinguishes the treatment paths being evaluated.

The registry’s participant-flow account illustrates why design structure and realized data must be considered together. Although the intervention descriptions include maintenance, augmentation, and switching options, the record says there were no nonresponders and no re-randomized participants. As a result, the later randomization features of the planned strategy are not represented in the reported participant flow. This is a key distinction between planning a sequential design and obtaining data across its intended decision points.

The primary endpoint is also statistically informative as a design choice. Recruitment, treatment delivery, and retention are practical prerequisites for a larger evaluation. Combining them into a feasibility composite can make implementation goals explicit, although component-level reporting is important for understanding which goals were achieved. The registry record does not report the numerical composite or its components, leaving the feasibility conclusion unresolved.

Finally, the study highlights the value of complete outcome and analysis reporting. The registry lists multiple clinical outcomes, but numerical results, uncertainty estimates, analysis populations, and missing-data methods are not reported. Without those details, readers can understand the intended research questions but cannot evaluate treatment effects or their precision. The record is therefore most useful as a description of a pilot design and its stated feasibility framework, rather than as evidence for a comparative clinical conclusion.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for statistical interpretation is that the numerical primary-endpoint result is not reported in the registry record. The composite’s component-level results and the rule for combining them are also not reported. This prevents assessment of whether recruitment, treatment completion, and retention met the stated feasibility goals.

Enrollment was 10 participants, and the adverse-event record lists five at risk in each initial group. This is a small pilot sample for estimating treatment effects or uncommon events. The record does not report confidence intervals or other measures of uncertainty, and it does not report a statistical analysis of the primary or secondary outcomes. No effect estimates can therefore be assessed for precision.

The adaptive strategy was not observed across its full set of decision points in the reported participant flow. The record states that no nonresponders were re-randomized to an augmented or changed treatment. This limits evaluation of later-stage strategies, including the listed CBT and mHealth options, through randomized comparisons.

Additional design and analysis details are not reported in the registry record, including eligibility criteria, randomization procedures, the identities of those masked, response definitions, analysis populations, missing-data handling, and multiplicity planning. The record also does not report the study’s own sample-size justification. These gaps limit reproducibility and make it difficult to judge the intended inferential framework. The limitations concern what can be concluded from the registry record; they do not determine what may have been observed or documented elsewhere.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: An Adaptive Intervention for Depression Among Latinos Living With HIV — NCT03668379.
• Registry record last updated 2024-10-21; status last verified 2024-10.
• Results first posted 2024-10-21.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed randomized, double-masked, sequential pilot study sponsored by the University of California, San Francisco. It enrolled 10 participants and examined an adaptive treatment strategy for depression and engagement in HIV care among Latinos living with HIV. The initial interventions were BAT alone and BAT with mHealth.

The primary endpoint was a four-month composite feasibility measure involving recruitment, treatment-session completion, and retention. The record says there were no nonresponders or re-randomized participants for later treatment changes. It lists secondary outcomes including ART adherence, viral load, PHQ-9, and engagement in HIV care.

Numerical primary and secondary outcome results, statistical analyses, uncertainty estimates, and analysis details are not reported in the registry record. The adverse-event listings report no serious events, other events, or deaths in either group.